Vedolizumab: Phase III started

Takeda began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 300 mg IV vedolizumab at weeks 0, 2 and 6 and every 8 weeks thereafter as an induction and maintenance therapy in ...